Cellosaurus logo
expasy logo

Cellosaurus JC053-DR2 (CVCL_C5U1)

[Text][XML][JSON]
Cell line name JC053-DR2
Accession CVCL_C5U1
Resource Identification Initiative To cite this cell line use: JC053-DR2 (RRID:CVCL_C5U1)
Comments Population: Japanese.
Selected for resistance to: ChEBI; CHEBI_75045; Dabrafenib (Tafinlar; GSK2118436).
Derived from site: In situ; Colon, transverse; UBERON=UBERON_0001157.
Sequence variations
  • Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=35724767).
  • Mutation; HGNC; HGNC:1097; BRAF; Unexplicit; Ex3-8del; Zygosity=Heterozygous (PubMed=35724767).
  • Mutation; HGNC; HGNC:1097; BRAF; Unexplicit; Ex4-8del; Zygosity=Heterozygous (PubMed=35724767).
Disease Colorectal neuroendocrine carcinoma (NCIt: C96156)
Neuroendocrine tumor of the colon (ORDO: Orphanet_100080)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_C5TZ (JC053)
Sex of cell Male
Age at sampling 21Y
Category Cancer cell line
Publications

PubMed=35724767; DOI=10.1016/j.canlet.2022.215799
Yuki Shimizu, Kohei Maruyama, Mai Suzuki, Hiroshi Kawachi, Siew-Kee Low, Tomoko Oh-hara, Kengo Takeuchi, Naoya Fujita, Satoshi Nagayama, Ryohei Katayama;
Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
Cancer Lett. 543:215799.1-215799.9(2022)

Cross-references
Encyclopedic resources Wikidata; Q116049600
Entry history
Entry creation15-Dec-2022
Last entry update19-Dec-2024
Version number4